



11th International
Respiratory Syncytial
Virus Symposium

Oct 31 - Nov 4, 2018
Omni Grove Park Inn
Asheville, NC USA



PROGRAM

DAY 1 Wednesday October 31

1400 - 1830	Registration & Poster Setup
1830 - 1845	Opening Address
	Introduction to Keynote Speaker
1845 - 1930	Keynote Address Recent Insights into the Structure, Function, and Antigenicity of the F and G Glycoproteins Dr Jason McLellan University of Texas at Austin, USA
1930 - 1945	In Memoriam: José Melero
1945 - 2115	Welcome Reception

End of Day 1

DAY 2 Thursday November 1

0630 - 0800	Breakfast
0700 - 1000	Registration & Poster Setup
0800 - 0930	SESSION 1 Clinical Impact and Epidemiology of RSV
0800 - 0830	Plenary I Strengthening Global RSV Surveillance: A Roadmap for the Future Dr Susan Gerber Centers for Disease Control and Prevention (CDC), USA
0830 - 0845	Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults (ARSVA0021) Dr Angela Branche University of Rochester, USA
0845 - 0900	Viral-bacterial interactions in infants with Respiratory Syncytial Virus Infection: Impact on clinical outcomes (ARSVA0149) Dr Asuncion Mejias The Research Institute at Nationwide Children's Hospital, USA
0900 - 0915	Evaluating the diagnostic performance of various case definitions in detecting respiratory syncytial virus infections among pediatric admissions to a referral hospital, coastal Kenya (ARSVA0168) Dr Patrick Munywoki Centers for Disease Control and Prevention (CDC), Kenya
0915 - 0930	Association of age at first severe RSV diseases with subsequent risk of asthma: a population-based cohort study (ARSVA0002) Dr Nusrat Homaira School of Women's and Children's Health, UNSW Medicine, Australia
0930 - 1000	Coffee break

1000 - 11.30 SESSION 2 Recent Developments in RSV Virology	
1000 - 1030	<p>Plenary 2</p> <p><i>Title of Talk - tbc</i></p> <p>Dr Gaya Amarasinghe Washington University, St. Louis, USA</p>
1030 - 1045	<p>Respiratory Syncytial Virus Binds to a Signaling Coreceptor which Induces Recruitment of its Receptor, Nucleolin, to the Cell Surface during Entry (ARSVA0194)</p> <p>Cameron Griffiths University of Alberta, Canada</p>
1045 - 1100	<p>Palladin mediates the association of RSV M protein with microfilaments in infected cells (ARSVA0236)</p> <p>Shadi Shahriari University of Canberra, Australia</p>
1100 - 1115	<p>Airway epithelial and immune cell responses to RSV G protein interaction with fractalkine receptor CX3CR1 (ARSVA0248)</p> <p>Dr. Tatiana Chirkova Emory University, USA</p>
1115 - 1130	<p>Ultrastructural Studies of RSV Assembly by Cellular Cryo-Electron Microscopy (ARSVA0251)</p> <p>Dr. Jie (Jae) Yang University of Wisconsin-Madison, USA</p>
1130 - 1230	Poster Session 1
1230 - 1330	Lunch Break
1330 - 1500 SESSION 3 Immune Response to RSV	
1330 - 1400	<p>Plenary 3</p> <p>Inflammasome Activation is Influenced by RSV Strain Differences</p> <p>Dr. Steven Varga University of Iowa, USA</p>
1400 - 1415	<p>Attenuation of human airway epithelial cell innate immune responses to respiratory syncytial virus (RSV) in newborn infants compared to older infants (ARSVA0050)</p> <p>Dr. Helen Groves Queen's University Belfast, UK</p>
1415 - 1430	<p>Unraveling the respiratory syncytial virus (RSV) antibody functional repertoire in adult healthy donors (ARSVA0085)</p> <p>Emanuele Andreano University of Siena, Italy</p>
1430 - 1445	<p>RSV infection in early life is associated with defective tissue resident memory T cell differentiation (ARSVA0156)</p> <p>Dr. Mathilde Turfkruyer-Hussor Uniformed Services University of the Health Sciences, USA</p>
1445 - 1500	<p>Identification of novel factors associated with severe RSV disease in infants (ARSVA00161)</p> <p>Dr. Ultan Power Queen's University Belfast, UK</p>
1500 - 1530	Coffee Break
1530 - 1630 SESSION 4 Novel RSV Monoclonal Antibodies	
1530 - 1600	<p>Plenary 4</p> <p><i>Title of Talk - tbc</i></p> <p>Dr. James Crowe Jnr Vanderbilt University Medical Center, USA</p>

1600 - 1615	Discovery and in vitro characterization of a potent broadly neutralizing antibody isolated from human memory B-cells (AROVA0041) Dr. Zhifeng Chen Merck & Co Inc.
1615 - 1630	A Phase 3, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Suptavumab, for the Prevention of Medically attended RSV Infection in Preterm Infants (AROVA0100) Dr. Eric Simoes Childrens Hospital, Colorado, USA
1630 - 1645	Title TBC Dr. Lindsay Broadbent Queen's University, Belfast, UK
1645 - 1815	SESSION 5 Advancements in RSV Vaccines
1645 - 1715	Plenary 5 Live Attenuated Pediatric RSV Vaccines Dr Ursula Buchholz NIH NIAID, USA
1715 - 1730	WHO 1st International Standard for Antiserum to RSV (AROVA0018) Dr. Jacqueline McDonald National Institute of Biological Standards and Control (NIBSC), UK
1730 - 1745	Intranasal RSV F bound to Lactococcal particles induces durable systemic immune responses in human volunteers (AROVA0183) Dr. Stephanie Ascough Imperial College London, UK
1745 - 1800	Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant (AROVA0189) Dr. Vivek Shinde Novavax Inc.
1800 - 1815	Janssen RSV Vaccine Program Dr. Myra Widjojoatmodjo Janssen Vaccines & Prevention B.V.
End of Day 2	
DAY 3 Friday November 2	
0630 - 0800	Breakfast
0800 - 0930	SESSION 6 RSV Protein Structure and Function
0800 - 0830	Plenary 6 RSV F Glycoprotein Structure Determines Vaccine Immunogenicity Dr Barney Graham NIH VRC, USA
0830 - 0845	RSV F and G sequence evolution over the past three RSV seasons (2015/16-2017/2018) in the United States and Puerto Rico and implications for mAb/vaccine development (AROVA0051) Dr. Hong Jin MedImmune / AstraZeneca
0845 - 0900	Characterization of Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein in RSV Infected Hematopoietic Cell Transplant Adults (AROVA0062) Dr. Xunyan Ye Baylor College of Medicine, USA

0900 - 0915	New Insights into RSV Entry: ATPase Sodium/Potassium-Transporting Subunit Alpha-1 (ATP1A1) is Important for Macropinocytic Entry of RSV (ARSVA0044) Matthias Lingemann National Institute of Allergy and Infectious Diseases, USA
0915 - 0930	The Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Is Critical for Fusion Activity (ARSVA0195) Dr. Mark Peeples The Ohio State University, USA
0930 – 1000	Coffee Break
1000 – 1130	SESSION 7 RSV Pathogenesis and Experimental Models
1000 - 1030	Plenary 7 RSV Pathogenesis, Prevention, and Animal Models Dr Marina Boukhvalova Sigmovir Biosystems, Maryland, USA
1030 - 1045	Respiratory syncytial virus (RSV) infection increases neutrophil trans-epithelial migration and adherence resulting in increased damage to ciliated airway epithelial cells (ARSVA0206) Dr. Claire Smith UCL GOS Institute of Child Health London, UK
1045 - 1100	Genetic determinants of severe respiratory syncytial virus infections in infants (ARSVA0072) Dr. Martin Wetzke Medical School Hannover, Germany
1100 - 1115	MUC5B is the predominant gel-forming mucin obstructing the distal airways during RSV bronchiolitis (ARSVA0209) Dr. Raymond Pickles UNC-Chapel Hill, NC, USA
1115 - 1130	Streptococcus Pneumoniae Infection in Respiratory Syncytial Virus Infected Neonatal Lambs (ARSVA0048) Dr. Sarhad Alnajjar Iowa State University, Oregon State University, USA
1130 - 1200	Coffee Break
1200 – 0130	SESSION 8 Anti-RSV Therapies
1200 - 1230	Plenary 8 <i>Title of Talk tbc</i> Dr. Janet Englund Seattle Children's Hospital, University of Washington
1230 - 1245	Efficacy of the non-fusion human respiratory syncytial virus (hRSV) replication inhibitor JNJ-64166037 in hRSV infected lamb model (ARSVA0005) Dr. Panchan Sitticharoenchai Iowa State University, USA
1245 - 1300	EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro (ARSVA0015) Dr. Michael Rhodin Enanta Pharmaceuticals, USA
1300 - 1315	Antiviral effects, pharmacokinetics (PK) and safety of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected infants with bronchiolitis, in the Phase 1b Study 53718678RSV1005 (ARSVA0016) Dr. Marita Stevens Janssen Infectious Diseases Bvba, Belgium
1315 - 1330	Ziresovir (AK0529): Update on Clinical Development for the Treatment of Respiratory Syncytial Virus (RSV) Disease (ARSVA0014) Dr Stephen Toovey Ark Biosciences, Switzerland
1330 - 1900	Afternoon Optional Activities
1900 – 2030	Robert M. Chanock Lectures
1900 - 1945	Title- TBC Dr. Ann Falsey University of Rochester Medical Center, USA

1945 - 2030	Title- TBC Dr. Edward Walsh University of Rochester Medical Center, USA
2030 - 2200	Poster Session 2 with Reception
End of Day 3	
DAY 4 Saturday November 3	
0630 - 0800	Breakfast
0800 - 0845	Keynote Address <i>Title of Talk</i> Katherine O'Brien MD Johns Hopkins University, USA
0845 - 0855	Short Break
0855 – 1010	SESSION 9 RSV Prophylaxis and Vaccines II
0855 - 0925	Plenary 9 <i>Title of Talk</i> Dr. Bernadette van den Hoogen Erasmus University, Netherlands
0925 - 0940	Defining the Humoral and B Cell Response after Vaccination with a Stabilized Prefusion RSV F Subunit Vaccine (DS-Cav1) (ARSVA0088) Emily Phung VRC; NIAID; NIH, USA
0940 - 0955	Evaluation of Novel RSV Live Attenuated Vaccine in a Non-Human Primate Model (ARSVA0245) Dr. Tiffany Jenkins Nationwide Children's Hospital Research Institute, OH, USA
0955 - 1010	Pfizer RSV Vaccine Program Kena Swanson Pfizer Vaccine Research
1010 - 1030	Coffee Break
1030 – 1200	SESSION 10 RSV's Global Impact and Epidemiology
1030 - 1100	Plenary 10 <i>Title of Talk tbc</i> Prof. D. James Nokes KEMRI-Wellcome Trust Research Programme, Kenya
1100 - 1115	Global and regional disease burden estimates of respiratory syncytial virus associated with acute respiratory infections in older adults in 2015: A systematic review and meta-analysis (ARSVA0012) Dr. Ting Shi University of Edinburgh, UK
1115 - 1130	Global patterns in monthly activity of respiratory syncytial virus: a systematic review and modelling study (ARSVA0036) You Li University of Edinburgh, UK
1130 - 1145	Prospective, epidemiological study of the incidence of respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) from birth up to 2 years of age in diverse global settings (ARSVA0176) Dr. Joanne Langley Dalhousie University, Canada

1145 - 1200	WHO Global RSV Surveillance based on GISRS – building evidence for policy Siddhivinayal Hirve World Health Organisation
1200 - 1300	Lunch Break
1300 - 1430	SESSION 11 Global Perspective of the RSV Problem
1300 - 1330	Plenary 11 RSV Prevention: How to Get from The Lab to The Village Dr. Daniel Feikin World Health Organisation, Switzerland
1330 - 1335	BMGF's vision on RSV Community Mortality Studies Dr. Keith Klugman Bill & Melinda Gates Foundation, USA
1335 - 1342	RSV Gold Natalie Mazur University Medical Center Utrecht
1342 - 1349	Argentina Site Fernando Polack Fundación Infant, Buenos Aires, Argentina
1349 - 1356	RSV Burden from the CHAMPS Study Dianna Blau CDC
1356 - 1403	RSV Burden from the ZPRIME Study Christopher Gill Boston University School of Public Health, USA
1403 - 1430	PANEL & DISCUSSION
1430 - 1500	Coffee Break
1500 - 1630	SESSION 12 Maternal Immunity and Maternal Vaccination
1500 - 1530	Plenary 12 Maternal Immunity and Vaccination Dr. Helen Chu University of Washington, USA
1530 - 1545	Transplacental Respiratory Syncytial Virus and Influenza Antibody Transfer in Alaska-Native Mother-Infant Pairs (ARSVA0247) Shari Cho University of Washington, USA
1545 - 1600	Efficacy of RSV Maternal Immunization Varies with the Version of the Prefusion F Antigen in Virus-like Particle Vaccine Candidates (ARSVA0063) Dr. Trudy Morrison University of Massachusetts Medical School, USA
1600 - 1615	Advancing Maternal Immunization and the RSV MI Roadmap (ARSVA0196) Deborah Higgins PATH, USA
1615 - 1630	Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants (ARSVA0204) Dr. Louis Fries III Novavax, Inc.
End of Day 4	
1800 - 2200	Ticketed SOCIAL EVENT – Conference Dinner at the Biltmore

DAY 5 Sunday November 4 - Departures